Keletso Mkhwanazi shares their experience receiving lenacapavir, a new HIV prevention injection. Experts indicate that while certain populations are at higher risk for HIV, the jab is available to anyone who is eligible. This article was originally published by Health-e News.

The Ministry of Health announced that demand for Lenacapavir, a new HIV prevention injection launched in April, is currently exceeding the available supply, particularly among men seeking the twice-yearly treatment. Dr. Herbert Kadama, who coordinates Pre-Exposure Prophylaxis (PrEP) at the Ministry, spoke at a meeting with HIV advocates, researchers, and policymakers about the situation.

Health educators and HIV/AIDS focal persons in the Karamoja sub-region are receiving training on the implementation of Lenacapavir, a new injectable drug for HIV prevention introduced by the Ministry of Health. This training, organized by the Uganda AIDS Commission in Moroto District, aims to equip health communication officers and focal persons with the necessary skills for the rollout of this six-month HIV prevention jab.

The GP Health Department reported that the rollout of Lenacapavir, an HIV prevention drug, exceeded its targets in the first month of implementation. This development indicates a positive response to the drug's introduction in the region.

The rollout of lenacapavir (LEN) in Gauteng has faced challenges, with patients in parts of Pretoria being turned away due to delays. It has been two weeks since the initiation of the vaccination program, but access remains limited for some individuals, according to Health-e News.

The Ministry of Health in Uganda has announced the arrival of an additional 19,200 doses of lenacapavir, a long-acting injectable drug for HIV prevention, due to increasing demand. This shipment is expected next month and will primarily be used for administering second injections to individuals already receiving the treatment.